Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$47.47
al cierre: Aug 22, 7:47 PM EDT
$47.06
-0.41-0.86%
Pre-comercialización: Aug 22, 7:47 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Exact Sciences Corp ha un obiettivo di prezzo di consenso pari a $68.62, stabilito in base alle ultime valutazioni degli analisti di 28. Le ultime 3 valutazioni degli analisti sono state rilasciate da BTIG, Piper Sandler y Evercore ISI Group il agosto 12, 2025, agosto 11, 2025 y agosto 8, 2025. Con un obiettivo di prezzo medio di $61.33 tra le BTIG, Piper Sandler y Evercore ISI Group, c'è un implicito 30.33% upside per Exact Sciences Corp da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
BTIG
Piper Sandler
Evercore ISI Group
UBS
RBC Capital
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Exact Sciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/12/2025 | 27.5% | BTIG | $65 → $60 | Maintains | Buy | |||
08/11/2025 | 27.5% | Piper Sandler | $70 → $60 | Maintains | Overweight | |||
08/08/2025 | 36% | Evercore ISI Group | $68 → $64 | Maintains | Outperform | |||
08/07/2025 | 12.62% | UBS | $61 → $53 | Maintains | Neutral | |||
08/07/2025 | -2.25% | RBC Capital | $54 → $46 | Maintains | Sector Perform | |||
08/07/2025 | 16.87% | Barclays | $65 → $55 | Maintains | Overweight | |||
07/08/2025 | 44.5% | Evercore ISI Group | $66 → $68 | Maintains | Outperform | |||
06/24/2025 | 38.12% | Barclays | $75 → $65 | Maintains | Overweight | |||
05/02/2025 | 59.37% | Barclays | $55 → $75 | Maintains | Overweight | |||
05/02/2025 | 14.75% | RBC Capital | $52 → $54 | Maintains | Sector Perform | |||
05/02/2025 | 40.25% | Evercore ISI Group | $60 → $66 | Maintains | Outperform | |||
05/02/2025 | 53% | Baird | $69 → $72 | Maintains | Outperform | |||
04/11/2025 | 27.5% | Guggenheim | $60 → $60 | Reiterates | Buy → Buy | |||
04/10/2025 | 16.87% | Barclays | $65 → $55 | Maintains | Overweight | |||
04/10/2025 | 27.5% | Mizuho | → $60 | Initiates | → Outperform | |||
03/13/2025 | 10.5% | RBC Capital | → $52 | Initiates | → Sector Perform | |||
02/26/2025 | 48.75% | Piper Sandler | $75 → $70 | Maintains | Overweight | |||
02/24/2025 | 55.12% | Scotiabank | $70 → $73 | Maintains | Sector Outperform | |||
02/20/2025 | 38.12% | B of A Securities | $72 → $65 | Maintains | Buy | |||
02/20/2025 | 38.12% | Barclays | $70 → $65 | Maintains | Overweight | |||
01/23/2025 | 48.75% | Barclays | → $70 | Initiates | → Overweight | |||
01/13/2025 | 38.12% | Benchmark | $65 → $65 | Reiterates | Buy → Buy | |||
12/13/2024 | 53% | B of A Securities | $75 → $72 | Maintains | Buy | |||
11/26/2024 | 82.75% | TD Cowen | $82 → $86 | Maintains | Buy | |||
11/26/2024 | 59.37% | BTIG | $65 → $75 | Maintains | Buy | |||
11/11/2024 | 59.37% | Piper Sandler | $85 → $75 | Maintains | Overweight | |||
11/06/2024 | 59.37% | Citigroup | $80 → $75 | Maintains | Buy | |||
11/06/2024 | 80.62% | Jefferies | $84 → $85 | Maintains | Buy | |||
11/06/2024 | 38.12% | BTIG | $82 → $65 | Maintains | Buy | |||
11/06/2024 | 42.37% | Stifel | $82 → $67 | Maintains | Buy | |||
11/06/2024 | 59.37% | Canaccord Genuity | $95 → $75 | Maintains | Buy | |||
11/06/2024 | 74.25% | TD Cowen | $90 → $82 | Maintains | Buy | |||
11/06/2024 | 38.12% | Goldman Sachs | $75 → $65 | Maintains | Buy | |||
11/06/2024 | 27.5% | Evercore ISI Group | $80 → $60 | Maintains | Outperform | |||
11/06/2024 | 38.12% | Craig-Hallum | $82 → $65 | Maintains | Buy | |||
11/06/2024 | 38.12% | Benchmark | $67 → $65 | Maintains | Buy | |||
11/06/2024 | 42.37% | Baird | $70 → $67 | Maintains | Outperform | |||
10/30/2024 | 91.25% | Bernstein | $75 → $90 | Maintains | Outperform | |||
10/29/2024 | 101.87% | Canaccord Genuity | $75 → $95 | Maintains | Buy | |||
10/01/2024 | 70% | Evercore ISI Group | $72 → $80 | Maintains | Outperform | |||
09/26/2024 | — | Raymond James | — | Reiterates | → Market Perform | |||
09/13/2024 | 59.37% | Canaccord Genuity | $75 → $75 | Maintains | Buy | |||
09/12/2024 | 80.62% | Piper Sandler | $75 → $85 | Maintains | Overweight | |||
08/27/2024 | 59.37% | Wells Fargo | → $75 | Initiates | → Overweight | |||
08/01/2024 | 42.37% | Benchmark | $91 → $67 | Maintains | Buy | |||
08/01/2024 | 74.25% | Stifel | $100 → $82 | Maintains | Buy | |||
07/17/2024 | 59.37% | Goldman Sachs | $88 → $75 | Maintains | Buy | |||
07/02/2024 | 53% | Evercore ISI Group | $80 → $72 | Maintains | Outperform | |||
06/27/2024 | 48.75% | BTIG | $80 → $70 | Maintains | Buy | |||
06/27/2024 | 48.75% | Scotiabank | → $70 | Initiates | → Sector Outperform | |||
06/26/2024 | 48.75% | BTIG | $80 → $70 | Maintains | Buy | |||
05/09/2024 | 70% | BTIG | $85 → $80 | Maintains | Buy | |||
05/09/2024 | 80.62% | Canaccord Genuity | $90 → $85 | Maintains | Buy | |||
05/09/2024 | 70% | Citigroup | $100 → $80 | Maintains | Buy | |||
04/03/2024 | 112.49% | Citigroup | → $100 | Maintains | Buy | |||
02/22/2024 | 91.25% | Canaccord Genuity | $100 → $90 | Maintains | Buy | |||
01/02/2024 | 93.37% | Benchmark | → $91 | Upgrade | Hold → Buy | |||
12/14/2023 | 91.25% | Guggenheim | → $90 | Initiates | → Buy | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Outperform | |||
11/03/2023 | 91.25% | Goldman Sachs | $100 → $90 | Maintains | Buy | |||
10/16/2023 | 70% | Piper Sandler | $90 → $80 | Maintains | Overweight | |||
10/10/2023 | 91.25% | Piper Sandler | → $90 | Upgrade | Neutral → Overweight | |||
09/28/2023 | 76.37% | Bernstein | → $83 | Initiates | → Outperform | |||
08/08/2023 | 91.25% | Piper Sandler | $80 → $90 | Maintains | Neutral | |||
08/03/2023 | 133.74% | Jefferies | $100 → $110 | Maintains | Buy | |||
08/02/2023 | 91.25% | Credit Suisse | $75 → $90 | Maintains | Neutral | |||
08/02/2023 | 157.12% | Baird | $99 → $121 | Maintains | Outperform | |||
08/02/2023 | — | Benchmark | — | Downgrade | Buy → Hold | |||
07/24/2023 | 133.74% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
07/21/2023 | 133.74% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
06/23/2023 | 144.37% | Canaccord Genuity | $92 → $115 | Maintains | Buy | |||
06/22/2023 | 176.24% | Citigroup | $100 → $130 | Maintains | Buy | |||
06/22/2023 | 103.99% | Benchmark | → $96 | Reiterates | Buy → Buy | |||
06/21/2023 | 80.62% | Stifel | → $85 | Reiterates | Buy → Buy | |||
06/21/2023 | 95.5% | Canaccord Genuity | → $92 | Reiterates | Buy → Buy | |||
06/07/2023 | 112.49% | Jefferies | $82 → $100 | Maintains | Buy | |||
05/11/2023 | 112.49% | Citigroup | $90 → $100 | Maintains | Buy | |||
05/10/2023 | 74.25% | Jefferies | $72 → $82 | Maintains | Buy | |||
05/10/2023 | 87% | B of A Securities | $80 → $88 | Maintains | Buy | |||
05/10/2023 | 59.37% | Credit Suisse | $70 → $75 | Maintains | Neutral | |||
05/10/2023 | 110.37% | Baird | $92 → $99 | Maintains | Outperform | |||
05/10/2023 | 80.62% | Craig-Hallum | $55 → $85 | Upgrade | Hold → Buy | |||
05/05/2023 | 55.12% | UBS | → $73 | Initiates | → Neutral | |||
03/15/2023 | 65.75% | Benchmark | $54 → $78 | Maintains | Buy | |||
03/09/2023 | 91.25% | Citigroup | $70 → $90 | Upgrade | Neutral → Buy | |||
03/03/2023 | 48.75% | Piper Sandler | $50 → $70 | Maintains | Neutral | |||
02/22/2023 | 61.5% | Cowen & Co. | $56 → $76 | Maintains | Outperform | |||
02/22/2023 | 95.5% | Baird | $89 → $92 | Maintains | Outperform | |||
02/22/2023 | 70% | BTIG | $85 → $80 | Maintains | Buy | |||
02/22/2023 | 59.37% | Canaccord Genuity | $70 → $75 | Maintains | Buy | |||
02/22/2023 | 48.75% | Citigroup | $35 → $70 | Maintains | Neutral | |||
02/22/2023 | 48.75% | Credit Suisse | → $70 | Reiterates | → Neutral | |||
02/10/2023 | 48.75% | Credit Suisse | $50 → $70 | Downgrade | Outperform → Neutral | |||
01/18/2023 | — | Raymond James | — | Downgrade | Outperform → Market Perform | |||
01/12/2023 | 59.37% | SVB Leerink | $70 → $75 | Maintains | Outperform | |||
01/06/2023 | 48.75% | SVB Leerink | $60 → $70 | Maintains | Outperform | |||
12/16/2022 | 48.75% | Jefferies | → $70 | Maintains | Buy | |||
11/14/2022 | 6.25% | Piper Sandler | $40 → $50 | Maintains | Neutral | |||
11/08/2022 | 27.5% | Raymond James | $70 → $60 | Maintains | Outperform | |||
11/07/2022 | 38.12% | BTIG | $70 → $65 | Maintains | Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Exact Sciences (EXAS)?
El último precio objetivo de Exact Sciences (NASDAQ:EXAS) fue comunicado por BTIG el agosto 12, 2025. La firma de analistas fijó un precio objetivo para $60.00 que espera EXAS a rise dentro de 12 meses (un posible 27.50% upside). 44 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Exact Sciences (EXAS)?
La última calificación de analistas para Exact Sciences (NASDAQ:EXAS) fue proporcionada por BTIG, y Exact Sciences mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Exact Sciences (EXAS)?
La última revisión al alza de Exact Sciences Corp se produjo en enero 2, 2024, cuando Benchmark elevó su precio objetivo a $91. Benchmark anteriormente tenía a hold para Exact Sciences Corp.
¿Cuándo fue la última revisión a la baja de Exact Sciences (EXAS)?
La última revisión a la baja de Exact Sciences Corp se produjo en agosto 2, 2023, cuando Benchmark cambió su precio objetivo de N/A a N/A para Exact Sciences Corp.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Exact Sciences (EXAS)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Exact Sciences, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Exact Sciences se registró el agosto 12, 2025, por lo que la próxima calificación estará disponible en torno al agosto 12, 2026.
¿Es correcta la calificación de los analistas sobre Exact Sciences (EXAS)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Exact Sciences (EXAS) fue un mantuvo con un precio objetivo de $65.00 a $60.00. El precio actual al que cotiza Exact Sciences (EXAS) es de $47.06, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.